213 related articles for article (PubMed ID: 38040699)
1. SMARCB1 loss activates patient-specific distal oncogenic enhancers in malignant rhabdoid tumors.
Liu NQ; Paassen I; Custers L; Zeller P; Teunissen H; Ayyildiz D; He J; Buhl JL; Hoving EW; van Oudenaarden A; de Wit E; Drost J
Nat Commun; 2023 Dec; 14(1):7762. PubMed ID: 38040699
[TBL] [Abstract][Full Text] [Related]
2. BRD9 defines a SWI/SNF sub-complex and constitutes a specific vulnerability in malignant rhabdoid tumors.
Wang X; Wang S; Troisi EC; Howard TP; Haswell JR; Wolf BK; Hawk WH; Ramos P; Oberlick EM; Tzvetkov EP; Ross A; Vazquez F; Hahn WC; Park PJ; Roberts CWM
Nat Commun; 2019 Apr; 10(1):1881. PubMed ID: 31015438
[TBL] [Abstract][Full Text] [Related]
3. Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases.
Holdhof D; Johann PD; Spohn M; Bockmayr M; Safaei S; Joshi P; Masliah-Planchon J; Ho B; Andrianteranagna M; Bourdeaut F; Huang A; Kool M; Upadhyaya SA; Bendel AE; Indenbirken D; Foulkes WD; Bush JW; Creytens D; Kordes U; Frühwald MC; Hasselblatt M; Schüller U
Acta Neuropathol; 2021 Feb; 141(2):291-301. PubMed ID: 33331994
[TBL] [Abstract][Full Text] [Related]
4. SMARCB1 is required for widespread BAF complex-mediated activation of enhancers and bivalent promoters.
Nakayama RT; Pulice JL; Valencia AM; McBride MJ; McKenzie ZM; Gillespie MA; Ku WL; Teng M; Cui K; Williams RT; Cassel SH; Qing H; Widmer CJ; Demetri GD; Irizarry RA; Zhao K; Ranish JA; Kadoch C
Nat Genet; 2017 Nov; 49(11):1613-1623. PubMed ID: 28945250
[TBL] [Abstract][Full Text] [Related]
5. SMARCB1-deficient Tumors of Childhood: A Practical Guide.
Pawel BR
Pediatr Dev Pathol; 2018; 21(1):6-28. PubMed ID: 29280680
[TBL] [Abstract][Full Text] [Related]
6. Pathology and diagnosis of SMARCB1-deficient tumors.
Margol AS; Judkins AR
Cancer Genet; 2014 Sep; 207(9):358-64. PubMed ID: 25246033
[TBL] [Abstract][Full Text] [Related]
7. A dynamic mutational landscape associated with an inter-regionally diverse immune response in malignant rhabdoid tumour.
Yasui H; Valind A; Karlsson J; Pietras C; Jansson C; Wille J; Romerius P; Backman T; Gisselsson D
J Pathol; 2020 Sep; 252(1):22-28. PubMed ID: 32542645
[TBL] [Abstract][Full Text] [Related]
8. Global Chromatin Changes Resulting from Single-Gene Inactivation-The Role of SMARCB1 in Malignant Rhabdoid Tumor.
Kenny C; O'Meara E; Ulaş M; Hokamp K; O'Sullivan MJ
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34071089
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of MYC attenuates tumor cell self-renewal and promotes senescence in SMARCB1-deficient Group 2 atypical teratoid rhabdoid tumors to suppress tumor growth in vivo.
Alimova I; Pierce A; Danis E; Donson A; Birks DK; Griesinger A; Foreman NK; Santi M; Soucek L; Venkataraman S; Vibhakar R
Int J Cancer; 2019 Apr; 144(8):1983-1995. PubMed ID: 30230537
[TBL] [Abstract][Full Text] [Related]
10. SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation.
Wang X; Lee RS; Alver BH; Haswell JR; Wang S; Mieczkowski J; Drier Y; Gillespie SM; Archer TC; Wu JN; Tzvetkov EP; Troisi EC; Pomeroy SL; Biegel JA; Tolstorukov MY; Bernstein BE; Park PJ; Roberts CW
Nat Genet; 2017 Feb; 49(2):289-295. PubMed ID: 27941797
[TBL] [Abstract][Full Text] [Related]
11. Genome-wide approach to identify second gene targets for malignant rhabdoid tumors using high-density oligonucleotide microarrays.
Takita J; Chen Y; Kato M; Ohki K; Sato Y; Ohta S; Sugita K; Nishimura R; Hoshino N; Seki M; Sanada M; Oka A; Hayashi Y; Ogawa S
Cancer Sci; 2014 Mar; 105(3):258-64. PubMed ID: 24418192
[TBL] [Abstract][Full Text] [Related]
12. Functional relevance of genes predicted to be affected by epigenetic alterations in atypical teratoid/rhabdoid tumors.
Tegeder I; Thiel K; Erkek S; Johann PD; Berlandi J; Thatikonda V; Frühwald MC; Kool M; Jeibmann A; Hasselblatt M
J Neurooncol; 2019 Jan; 141(1):43-55. PubMed ID: 30446899
[TBL] [Abstract][Full Text] [Related]
13. Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours.
Rao Q; Xia QY; Wang ZY; Li L; Shen Q; Shi SS; Wang X; Liu B; Wang YF; Shi QL; Ma HH; Lu ZF; He Y; Zhang RS; Yu B; Zhou XJ
Histopathology; 2015 Jul; 67(1):121-9. PubMed ID: 25496315
[TBL] [Abstract][Full Text] [Related]
14. Somatic mutations and single-cell transcriptomes reveal the root of malignant rhabdoid tumours.
Custers L; Khabirova E; Coorens THH; Oliver TRW; Calandrini C; Young MD; Vieira Braga FA; Ellis P; Mamanova L; Segers H; Maat A; Kool M; Hoving EW; van den Heuvel-Eibrink MM; Nicholson J; Straathof K; Hook L; de Krijger RR; Trayers C; Allinson K; Behjati S; Drost J
Nat Commun; 2021 Mar; 12(1):1407. PubMed ID: 33658498
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors.
Wöhrle S; Weiss A; Ito M; Kauffmann A; Murakami M; Jagani Z; Thuery A; Bauer-Probst B; Reimann F; Stamm C; Pornon A; Romanet V; Guagnano V; Brümmendorf T; Sellers WR; Hofmann F; Roberts CW; Graus Porta D
PLoS One; 2013; 8(10):e77652. PubMed ID: 24204904
[TBL] [Abstract][Full Text] [Related]
16. SNF5 reexpression in malignant rhabdoid tumors regulates transcription of target genes by recruitment of SWI/SNF complexes and RNAPII to the transcription start site of their promoters.
Kuwahara Y; Wei D; Durand J; Weissman BE
Mol Cancer Res; 2013 Mar; 11(3):251-60. PubMed ID: 23364536
[TBL] [Abstract][Full Text] [Related]
17. High prevalence of SMARCB1 constitutional abnormalities including mosaicism in malignant rhabdoid tumors.
Shirai R; Osumi T; Terashima K; Kiyotani C; Uchiyama M; Tsujimoto S; Yoshida M; Yoshida K; Uchiyama T; Tomizawa D; Shioda Y; Sekiguchi M; Watanabe K; Keino D; Ueno-Yokohata H; Ohki K; Takita J; Ito S; Deguchi T; Kiyokawa N; Ogiwara H; Hishiki T; Ogawa S; Okita H; Matsumoto K; Yoshioka T; Kato M
Eur J Hum Genet; 2020 Aug; 28(8):1124-1128. PubMed ID: 32218533
[TBL] [Abstract][Full Text] [Related]
18. SNF5/INI1 deficiency redefines chromatin remodeling complex composition during tumor development.
Wei D; Goldfarb D; Song S; Cannon C; Yan F; Sakellariou-Thompson D; Emanuele M; Major MB; Weissman BE; Kuwahara Y
Mol Cancer Res; 2014 Nov; 12(11):1574-85. PubMed ID: 25009291
[TBL] [Abstract][Full Text] [Related]
19. Phosphoproteomic analysis reveals Smarcb1 dependent EGFR signaling in Malignant Rhabdoid tumor cells.
Darr J; Klochendler A; Isaac S; Geiger T; Eden A
Mol Cancer; 2015 Sep; 14():167. PubMed ID: 26370283
[TBL] [Abstract][Full Text] [Related]
20. Timing of Smarcb1 and Nf2 inactivation determines schwannoma versus rhabdoid tumor development.
Vitte J; Gao F; Coppola G; Judkins AR; Giovannini M
Nat Commun; 2017 Aug; 8(1):300. PubMed ID: 28824165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
